



Established: 2016

Employees: 4

Medical Device company

Milestones

Founded

February 2016

NIH Phase I SBIR

September 2018

First employees

January 2019

Imaging device FDA

December 2021 submission

Ablation Device FDA

December 2022 submission

Management

Mission & Vision

ElectroSonix is developing noninvasive, high resolution cardiac imaging technologies that will benefit millions of patients with abnormal heart rhythms.

Market Opportunity

2018:

- >30M patients with cardiac arrhythmias
- >1M catheter ablation procedures/year
- \$1.8B cardiac imaging market 4% CAGR
- \$2B cardiac ablation market 8% CAGR

Intellectual Property

- 2 granted US patents
 - US 8,057,390 High-resolution mapping of bio-electric fields
 - US 8,427,906 Acoustic sensor utilizing acoustoelectric effect
- 3 filed PCT patents

Advantages

Orders of magnitude improvement in imaging speed and accuracy over competition.

Products

We are building real-time, high-resolution imaging of electrical signals in the heart for feedback during ablation therapy. With faster and more accurate electrical mapping, this will reduce the number of ablations per procedure, procedure time, return procedures, as well as serious complications.

Ultrasound/Acoustoelectric Cardiac Imaging (ACI)

Target price \$45k


Cardiac Ablation Device

Target price \$250k w/ disposable catheter


Catheters

Target price \$2k

ACI during ECG



ECG



Pierre Landau, PhD
CEO & President
Entrepreneur, computer scientist, Telehealth, ISO 13485 and FDA clearance



Russ Witte, PhD
Founder & CSO
Assoc. Professor, Medical Imaging, Optical Sciences & Biomedical Engineering, UA



Sonia Vohnout
COO & VP
Entrepreneur, business development, systems engineering, project management

Scientific Advisors

Aiden Abidov, MD
Benigno Decena, MD
John Michels, MD
Talal Moukabary, MD
Matt O'Donnell, PhD

Advisory Board

Jim Cantrell, CEO Vector Launch
Marie Wesselhoft, CEO MSDx
Mack Consigny, PhD
Tech Launch Arizona